Table I.

Body surface area and static investigator global assessment score^∗

Week(s)	Body surface area (%)§	Investigator global assessment§
0†	12	3
4	7	3
16	7	3
28‡	7	3
32	3	3
40	1	2
48	1	2

^∗5-point investigator global assessment score.

^†First dose of ustekinumab administered.

^‡First dose of guselkumab administered.

^§Concomitant ultrapotent topical steroids were used.